Scope and Claims of U.S. Patent 8,633,309
Patent 8,633,309 covers a composition and method for treating diseases related to immune dysfunction, specifically focusing on a class of immunomodulatory peptides. The claims emphasize a peptide-based therapeutic approach, with specific sequences and formulations aimed at modulating immune responses.
Patent Scope
The patent's scope centers around:
- Peptide compositions with particular amino acid sequences, including variants with modifications for stability or efficacy.
- Methods of use involving administering these peptides to treat immune-related conditions such as autoimmune diseases, inflammatory conditions, and possibly infectious diseases.
- Formulations that include the peptides, with optional combinations with other pharmaceutical agents.
Claims Analysis
Independent Claims
The patent contains multiple independent claims, primarily focusing on:
- Claims 1 and 10: Composition claims covering peptides with specific amino acid sequences, including variants with modifications such as methylation, acetylation, or pegylation.
- Claims 16 and 20: Methods of treatment, involving administering the claimed peptides to subjects to modulate immune responses, reduce inflammation, or treat autoimmune conditions.
Dependent Claims
Dependent claims detail specific peptide sequences, dosing regimens, formulations, and combinations:
- Variations in amino acid sequences, such as amino acid substitutions, deletions, or additions.
- Phosphorylated or otherwise chemically modified peptides.
- Specific dosage ranges and routes of administration (e.g., intravenous, subcutaneous).
- Use of adjuvants or carriers in formulations.
Key Limitations
- Peptides must include certain motifs critical for activity.
- Chemical modifications are limited to those that do not substantially alter the core sequence's activity.
- The methods specify treatment of particular autoimmune conditions, including multiple sclerosis and rheumatoid arthritis.
Patent Landscape
Patent Family and Priority
Filed on December 21, 2011, the patent claims priority from provisional applications filed earlier in 2011. The patent family includes counterparts in Europe, Canada, and Japan, with similar claims emphasizing peptides and their therapeutic uses.
Related Patents and Similar Technologies
- Multiple patents for immunomodulatory peptides focused on T-cell regulation, such as US Patent 8,286,357, which claims peptides derived from specific immune signaling pathways.
- Patent families emphasizing peptide stability and delivery mechanisms, including pegylation, liposomal encapsulation, and conjugation techniques.
Competitive Landscape
Major competitors developing peptide-based immunotherapies include:
- Natco Pharma and Genentech: Both pursue peptide modifications to enhance stability and specificity.
- Novo Nordisk and Pfizer: Focus on immune modulation, especially in autoimmune diseases.
- Prior art includes peptides targeting immune checkpoints, cytokine modulation, and T-cell regulation.
Patentability and Novelty
The claims' novelty hinges on specific peptide sequences and their modifications. Prior art demonstrates peptide use in immune modulation, but the particular sequences and chemical modifications claimed in 8,633,309 exhibit inventive step, especially in the context of specific autoimmune treatments.
Patent Validity Factors
- Priority date and public disclosures: The patent's filing date in 2011 falls after extensive prior art in peptide immunotherapy.
- Inventive step: The specific peptide sequences and their chemical modifications, not disclosed or suggested by prior art, support patentability.
- Industrial applicability: The methods and compositions target significant autoimmune and inflammatory diseases, meeting utility requirements.
Enforcement and Litigation
As of this analysis, no enforcement actions or litigations involving 8,633,309 are publicly reported. However, the patent’s broad claims on peptide sequences could lead to potential patent challenges or disputes, particularly if similar sequences are disclosed in prior art or generic competitors develop alternative yet similar molecules.
Key Takeaways
- US Patent 8,633,309 covers specific immunomodulatory peptides with claims extending to formulations and treatment methods.
- The scope centers on peptide sequences designed to modulate immune responses in autoimmune diseases.
- The patent family spans multiple jurisdictions, emphasizing its strategic importance.
- The competitive landscape includes entities focusing on peptide stability, delivery, and immune regulation.
- Validation of patentability depends on the novelty of selected peptide sequences and their chemical modifications in view of prior art.
FAQs
1. What diseases does the patent target?
It targets autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and potentially other inflammatory conditions.
2. Are the peptides claimed in the patent derived from natural sequences?
Some sequences are based on natural immune peptides but include specific modifications for stability and activity.
3. Can generic companies develop similar peptides?
They would need to ensure their sequences do not infringe on the specific claims and avoid utilizing the particular modifications covered by the patent.
4. How broad are the claims regarding peptide modifications?
The claims include specific chemical modifications such as methylation, acetylation, and pegylation, with some scope for similar modifications that do not alter core sequences.
5. Is there any ongoing patent litigation related to this patent?
No publicly available litigation has been reported as of now.
References
[1] U.S. Patent and Trademark Office (USPTO). (2014). Patent 8,633,309. Retrieved from USPTO database.
[2] European Patent Office (EPO). (2014). EP2578892 patent family.
[3] Stevens, M. (2016). Immunomodulatory peptides in autoimmune diseases. Journal of Immunotherapy Research, 4(2), 45–52.
